KORSUVA (difelikefalin)

Medical Administration – Intravenous

Diagnosis considered for coverage: 

•    Chronic kidney disease (CKD): Indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).

Limitations of use: Korsuva has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.

Coverage Criteria:

For diagnosis of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD):

  • Dose does not exceed 0.5 mcg/kg IV bolus into the venous line of the dialysis circuit at the end of each HD treatment, AND
  • Patient is 18 years of age or older, AND
  • Prescribed by or in consultation with a nephrologist or dermatologist, AND
  • Diagnosis of chronic kidney disease (CKD), AND
  • Patient is currently undergoing hemodialysis (HD) at an optimal dialysis dose (e.g., Kt/V greater than or equal to 1.2), AND
  • Patient is experiencing moderate to severe pruritus associated with CKD (CKD-aP), AND
  • Exclusion of other causes of pruritus (e. g., eczema, infections, drug-induced skin dryness), AND
  • Trial and failure, contraindication, or intolerance to ONE topical anti-pruritic treatment:
    • emollient cream
    • analgesics (e.g., pramoxine lotion, capsaicin),
    • corticosteroids (e.g., hydrocortisone, triamcinolone), AND
  • Trial and failure, contraindication, or intolerance to ONE oral treatment:
    • antihistamine (e.g., diphenhydramine, hydroxyzine, loratadine)
    • gabapentin
    • pregabalin
Reauthorization Criteria:

For diagnosis of pruitus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD):

  • Dose does not exceed 0.5 mcg/kg IV bolus into the venous line of the dialysis circuit at the end of each HD treatment, AND
  • Patient is currently undergoing hemodialysis, AND
  • Documentation of positive clinical response to therapy (e.g., improved quality of life, improved worst itching intensity numerical rating score from baseline)
Coverage Duration: 
  • Initial: 3 months
  • Reauthorization: 12 months

Authorization is not covered for the following:
The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • Korsuva is removed by the dialyzer membrane and must be administered after blood is no longer circulating through the dialyzer.
Policy Updates:
  • 08/16/2022 – New policy approved by P&T.
References:
  • Korsuva Prescribing Information. Cara Therapeutics, Inc. Stamford, CT. August 2021. 
  • Davison SN, Levin A, Moss AH, et al. Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care. Kidney International. 2015;88(3):447-459. 
  • Ragazzo J, Cesta A, Jassal SV, Chiang N, Battistella M. Development and Validation of a Uremic Pruritus Treatment Algorithm and Patient Information Toolkit in Patients With Chronic Kidney Disease and End Stage Kidney Disease. Journal of Pain and Symptom Management. 2020;59(2):279-292.e5. 
  • Hemodialysis: Dose & Adequacy | NIDDK. National Institute of Diabetes and Digestive and Kidney Diseases. Accessed April 4, 2022

Last review date: August 16, 2022

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone